Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

Healthcare Biotechnology
iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Satellos Bioscience Inc Com > Gilead Sciences (GILD) boasting a 92 billion dollar market
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(7)
•••
Comment by allain250on Jul 11, 2018 10:30am
88 Views
Post# 28299258

RE:Gilead Sciences (GILD) boasting a 92 billion dollar market

RE:Gilead Sciences (GILD) boasting a 92 billion dollar market

ICO is about to KIDNAP a HUGE established market with this new research!
 

DoubleBank Believes the following Scheduled Clinical Trial Reports due this July will prove Explosive concerning the Stock Price of ICO We cannot predict how high ICO stock will travel long term. Although this is a forward looking statement we have every reason to believe stock holders will see nothing but positive results concerning medical trials that have just concluded in Australia on behalf of Ico Therapeutics. The next 2 soon to be seen milestones are a follows: 

 

1.   ORAL B  material pharmacokinetic data to be released in July

2. Bullous Pemphigoid Disease BP-01 material pharmacokinetic data to be released in July

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities